case_images: PMC8019780_01
case_images: PMC8019780_02
case_images: Coronal (A) and axial (B) representative images from the patient's pre-treatment CT scan.
case_images: fimmu-12-660795-g001.jpg
case_images: PMC8019780_02_fimmu-12-660795-g001.jpg
case_images: f1
case_images: Computed tomography (CT) of the chest demonstrated diffuse nodular ground-glass infiltrates and widespread nodularity bilaterally (Figure 1).
case_images: PMC8019780_03
case_images: PMC8019780_04
case_images: PMC8019780_05
case_images: Change in serum LDH over time. The green data point represents initial diagnosis and initiation of treatment with trametinib. Red data points represent dates that pembrolizumab was administered. Dotted line represents upper limit of normal LDH (241 IU/L).
case_images: fimmu-12-660795-g002.jpg
case_images: PMC8019780_05_fimmu-12-660795-g002.jpg
case_images: f2
case_images: Follow up bloodwork revealed a precipitous drop in the serum lactic dehydrogenase (LDH), eventually below the upper limit of normal (Figure 2).
case_images: Timeline representation of the case.
case_images: fimmu-12-660795-g003.jpg
case_images: PMC8019780_05_fimmu-12-660795-g003.jpg
case_images: f3
case_images: A graphical representation of the case is shown in Figure 3.